Valuation : argenx SE

Market Cap 64.94B 55.88B 52.58B 48.03B 89.85B 6,132B 90.1B 621B 241B 3,146B 244B 239B 10,135B P/E 2026 *
36.9x
P/E 2027 * 29.3x
Enterprise Value 60.02B 51.64B 48.59B 44.39B 83.03B 5,667B 83.26B 574B 223B 2,907B 225B 220B 9,366B EV / Sales 2026 *
9.64x
EV / Sales 2027 * 7.45x
Free-Float
99.99%
Yield 2026 *
0.04%
Yield 2027 * 0.08%

Last Transcript : argenx SE

1 day-2.06%
1 week-0.18%
Current month+2.06%
1 month+22.75%
3 months+22.61%
6 months+39.10%
Current year+24.67%
1 week 866.8
Extreme 866.8
925
1 month 723.4
Extreme 723.4
925
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Exercice

Director

4,680 0.0076%
11/23/25 Exercice

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%-0.18%+41.53%+88.17% 66.32B
-1.79%-2.27%+50.90%+89.03% 69.02B
-0.31%+6.54%-11.39%+457.82% 27.66B
-3.00%-2.90%+39.40%+9.41% 26.54B
+0.86%+1.65%+0.25%-14.78% 25.84B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-15.21%+210.71%+370.84% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
-0.20%+8.37%+57.87%+159.50% 14.65B
+2.77%+28.22%-26.03%+980.06% 13.67B
Average -0.96%+1.64%+38.69%+265.16% 29.69B
Weighted average by Cap. -1.33%+0.57%+39.40%+183.39%

Financials

2026 *2027 *
Net sales 6.22B 5.36B 5.04B 4.6B 8.61B 588B 8.63B 59.54B 23.1B 301B 23.37B 22.86B 971B 7.73B 6.65B 6.26B 5.72B 10.69B 730B 10.72B 73.93B 28.69B 374B 29.02B 28.39B 1,206B
Net income 1.87B 1.61B 1.52B 1.38B 2.59B 177B 2.6B 17.9B 6.95B 90.65B 7.03B 6.87B 292B 2.51B 2.16B 2.03B 1.86B 3.47B 237B 3.48B 24.01B 9.32B 122B 9.43B 9.22B 392B
Net Debt -4.93B -4.24B -3.99B -3.64B -6.82B -465B -6.83B -47.13B -18.29B -239B -18.5B -18.1B -769B -7.39B -6.36B -5.98B -5.46B -10.22B -698B -10.25B -70.68B -27.43B -358B -27.74B -27.14B -1,153B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-09-04 €893.60 -2.06% 55,862
26-09-03 €912.40 +1.31% 98,423
26-09-02 €900.60 +1.62% 64,529
26-09-01 €886.20 +1.21% 56,481
26-08-31 €875.60 -2.19% 136,880
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1,038.47USD
Average target price
1,162.61USD
Spread / Average Target
+11.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock